CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-23 | Huntsman Carole Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +5,483 | 5,483 | ||
| 2024-01-23 | Huntsman Carole Chief Commercial Officer | Grant or award · Market Stock Unit | +3,639 | 3,639 | ||
| 2024-01-23 | Taub Rebecca Pres., R&D, and CMO | Grant or award | +5,786 | 20,787 | ||
| 2024-01-23 | Taub Rebecca Pres., R&D, and CMO | Grant or award · Stock Option (Right to Buy) | +8,718 | 8,718 | ||
| 2024-01-23 | Taub Rebecca Pres., R&D, and CMO | Grant or award · Market Stock Unit | +5,786 | 5,786 | ||
| 2024-01-23 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Grant or award | +1,419 | 6,536 | ||
| 2024-01-23 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Grant or award · Stock Option (Right to Buy) | +2,138 | 2,138 | ||
| 2024-01-23 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Grant or award · Market Stock Unit | +1,419 | 1,419 | ||
| 2024-01-23 | Howarth Alex G. Chief Financial Officer | Grant or award | +4,803 | 18,737 | ||
| 2024-01-23 | Howarth Alex G. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +7,238 | 7,238 | ||
| 2024-01-23 | Howarth Alex G. Chief Financial Officer | Grant or award · Market Stock Unit | +4,803 | 4,803 | ||
| 2024-01-23 | Lynch Brian Joseph SVP and General Counsel | Grant or award | +3,639 | 17,691 | ||
| 2024-01-23 | Lynch Brian Joseph SVP and General Counsel | Grant or award · Stock Option (Right to Buy) | +5,483 | 5,483 | ||
| 2024-01-23 | Lynch Brian Joseph SVP and General Counsel | Grant or award · Market Stock Unit | +3,639 | 3,639 | ||
| 2024-01-23 | Sibold William John President and CEO | Grant or award | +12,250 | 62,250 | ||
| 2024-01-23 | Sibold William John President and CEO | Grant or award · Stock Option (Right to Buy) | +18,459 | 18,459 | ||
| 2024-01-23 | Sibold William John President and CEO | Grant or award · Market Stock Unit | +12,250 | 12,250 | ||
| 2024-01-16 | Lynch Brian Joseph SVP and General Counsel | Shares withheld for taxes | −949 | $243.92 | $231K | 14,052 |
| 2024-01-16 | Taub Rebecca Pres., R&D, and CMO | Shares withheld for taxes | −1,546 | $243.92 | $377K | 15,001 |
| 2024-01-16 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Shares withheld for taxes | −550 | $243.92 | $134K | 5,117 |
Page 37 of 82 · 1,629 trades